SETD8 Methylation: A Promising Drug Target (G387893)

Target Name: KMT5A

NCBI ID: G387893

KMT5A

SETD8 Methylation: A Promising Drug Target

Histone-lysine N-methyltransferase SETD8 (KMT5A) is a gene that has been well-studied for its role in various cellular processes, including the regulation of cell growth, differentiation, and DNA replication. Mutations in the SETD8 gene have been linked to a range of diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, KMT5A has emerged as a promising drug target for a variety of therapeutic applications.

The SETD8 gene is a member of the KMT family of DNA polymerases, which are responsible for the repetitive DNA structure in the nucleus of the cell. The KMT family is characterized by the presence of a specific domain called the \"SETD8-specific domain, \" which is responsible for the transfer of methyl groups to specific lysine residues on histones. This domain is unique to the KMT family and allows for the specificity of SETD8 methylation.

SETD8 methylation is critical for the regulation of various cellular processes, including cell growth, differentiation, and DNA replication. During cell growth, the SETD8 gene is transcribed into RNA and then translated into histone-lysine N-methyltransferase, which adds methyl groups to specific lysine residues on histones. This process is essential for the regulation of cell size and the maintenance of tissue architecture. Methylation of the histone N-terminus has been shown to play a role in the regulation of microtubule dynamics and the dynamics of the nuclear envelope during cell division.

In addition to its role in cell growth and differentiation, SETD8 methylation has also been linked to the regulation of DNA replication. Methylation of the histone N-terminus has been shown to play a role in the regulation of DNA replication by the RAD50 protein. RAD50 is a protein that is involved in the repair of DNA damage and is composed of several subunits, including a DNA-binding subunit and a protein that can form a complex with the histone N-terminus. Methylation of the histone N-terminus has been shown to prevent RAD50 from binding to the DNA and to inhibit its ability to repair DNA damage.

SETD8 methylation has also been linked to the regulation of cellular signaling pathways. For example, SETD8 methylation has been shown to play a role in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cellular signaling pathways that are important for various cellular processes, including cell growth, differentiation, and survival. Methylation of the SETD8 gene has been shown to inhibit the activity of the Akt kinase, which is a key enzyme in the PI3K/Akt signaling pathway.

In addition to its role in cellular signaling pathways, SETD8 methylation has also been linked to the regulation of cellular organization. For example, SETD8 methylation has been shown to play a role in the regulation of the organization of the nuclear envelope during cell division. cell division, the nuclear envelope is organized into a specific structure that is involved in the regulation of cell division. Methylation of the histone N-terminus has been shown to prevent the nuclear envelope from being properly organized and to result in the failure of cell division.

In conclusion, SETD8 gene is a promising drug target for various therapeutic applications. The SETD8 gene is involved in the regulation of cell growth, differentiation, DNA replication and cellular signaling pathways. KMT5A has been shown to play a critical role in the regulation of cell size, tissue architecture, and

Protein Name: Lysine Methyltransferase 5A

Functions: Protein-lysine N-methyltransferase that monomethylates both histones and non-histone proteins (PubMed:12086618, PubMed:12121615, PubMed:15964846, PubMed:17707234, PubMed:27338793). Specifically monomethylates 'Lys-20' of histone H4 (H4K20me1) (PubMed:12086618, PubMed:12121615, PubMed:15964846, PubMed:27338793, PubMed:15200950, PubMed:15933069, PubMed:15933070, PubMed:16517599). H4K20me1 is enriched during mitosis and represents a specific tag for epigenetic transcriptional repression (PubMed:12086618, PubMed:12121615, PubMed:15964846, PubMed:15200950, PubMed:15933069, PubMed:15933070, PubMed:16517599). Mainly functions in euchromatin regions, thereby playing a central role in the silencing of euchromatic genes (PubMed:12086618, PubMed:12121615, PubMed:15964846, PubMed:15200950, PubMed:15933069, PubMed:15933070, PubMed:16517599). Required for cell proliferation, probably by contributing to the maintenance of proper higher-order structure of DNA during mitosis (PubMed:12086618, PubMed:12121615, PubMed:15964846, PubMed:15200950, PubMed:15933069, PubMed:15933070, PubMed:16517599). Involved in chromosome condensation and proper cytokinesis (PubMed:12086618, PubMed:12121615, PubMed:15964846, PubMed:15200950, PubMed:15933069, PubMed:15933070, PubMed:16517599). Nucleosomes are preferred as substrate compared to free histones (PubMed:12086618, PubMed:12121615, PubMed:15964846, PubMed:15200950, PubMed:15933069, PubMed:15933070, PubMed:16517599). Mediates monomethylation of p53/TP53 at 'Lys-382', leading to repress p53/TP53-target genes (PubMed:17707234). Plays a negative role in TGF-beta response regulation and a positive role in cell migration (PubMed:23478445)

The "KMT5A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KMT5A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets